{
  "docId": "019de070-35c1-7439-bbdc-1b157563e1ac",
  "docSlug": "efb4ac2b8ef2465cd20aa5f0f0b26fe6",
  "documentTitle": "Poseida Therapeutics | IPO Presentation Deck | 34 slides",
  "authorId": "poseida-therapeutics",
  "authorName": "Poseida Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 34,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide acts as a high-level summary of the company's value proposition and asset structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-35c1-7439-bbdc-1b157563e1ac/5",
  "deckHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac",
  "deckJsonHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac.json",
  "deckAnchorHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.34,
        "y": 0.07
      },
      "kind": "image",
      "text": "POSEIDA THERAPEUTICS",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "156234c4-6486-454b-b000-111bc9238754",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.36,
        "x": 0.09,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "CELL THERAPY: Deep pipeline of CAR-T product candidates (autologous -> allogeneic)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e075f59-ee96-4528-bfc6-d11da6066fc8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.36,
        "x": 0.54,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "GENE THERAPY: Pipeline of GENE THERAPY product candidates (in vivo liver-directed therapies)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdc47f30-c5f7-489b-aecd-eec601a38dd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.72,
        "x": 0.14,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Currently Unpartnered and Wholly-owned Assets. Significant Future Growth Potential Powered by Broad Platform Technology",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3495bbc-f729-412f-8fe2-f599975eeefd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.64,
        "x": 0.18,
        "y": 0.25
      },
      "kind": "title",
      "text": "Clinical Stage Company with Broad Suite of Proprietary Gene Engineering Technology Platforms to deliver:",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7eb40159-318e-40f0-b193-4947411ae657",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "5f413939-fc8e-43a3-886d-1b62f8e2b47d",
      "evidence": "paragraph/paragraph: Currently Unpartnered and Wholly-owned Assets. Significant Future Growth Potential Powered by Broad Platform Technology",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "8f16d6f5-9b92-4393-a4e9-27854dd971ae",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Introduction to Poseida Therapeutics and the competitive cell and gene therapy space",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6f9cad02-adae-4a5c-9270-7743f08375ff",
      "evidence": "Introduction to Poseida Therapeutics and its proprietary technologies",
      "position": 1,
      "objective": "Why is Poseida Therapeutics well-positioned in the cell and gene therapy space?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}